KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 113 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $975,222 | -75.7% | 108,358 | -81.8% | 0.01% | -77.8% |
| Q4 2022 | $4,014,156 | -63.3% | 593,810 | -21.1% | 0.05% | -64.7% |
| Q3 2022 | $10,924,000 | +2.1% | 752,881 | -30.7% | 0.15% | -7.3% |
| Q2 2022 | $10,695,000 | +46.0% | 1,086,883 | +118.7% | 0.16% | +38.7% |
| Q1 2022 | $7,326,000 | +299.0% | 497,014 | +258.2% | 0.12% | +357.7% |
| Q4 2021 | $1,836,000 | -18.7% | 138,738 | +7.3% | 0.03% | -29.7% |
| Q3 2021 | $2,257,000 | -7.4% | 129,351 | +27.2% | 0.04% | -17.8% |
| Q2 2021 | $2,437,000 | -57.7% | 101,706 | -54.6% | 0.04% | -64.8% |
| Q1 2021 | $5,756,000 | – | 224,059 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |